Initial management of overactive bladder includes behavioural modifications, urge inhibition and pharmacotherapy. until recently, antimuscarinics have been cornerstone pharmacotherapeutic agents. their long term usage has been limited due to side effects particularly, but not limited to, constipation, dry mouth, cognitive impairment and tachycardia. Mirabegron, a beta3 agonist, is new kid on the block been available in India since mid 2018. The potential benefits over antimuscarics are significantly less side effects and equivalent efficacy. the potential side effect of hypertension has not been found significant over placebo. Already found a place as second line therapy and comination therapy, it is increasingly being accepted as first line alternative.